Look Out Mako, Here Comes Rosa

An industry analyst expects Zimmer Biomet’s Rosa Knee robotic system to represent a formidable competitor to Stryker’s Mako Knee after the Rosa Knee’s full launch later this year. However, both Mako and Rosa have their strengths and weaknesses, and neither is clearly superior, the analyst said.

Surgical robotics is hotter than ever this year, particularly on the orthopedics side, and Zimmer Biomet is about to crank up the heat even more. The Warsaw, IN-based is expected to initiate a full launch of its Rosa Knee robotics system in the back half of the year.

FDA cleared the system for use in robotically-assisted total knee replacement procedures in January, but Zimmer Biomet took a disciplined approach to commercialization.

“We’re going to do a limited launch out of the gate,” Zimmer Biomet CEO Bryan Hanson said during a Feb. 1 earnings call. “We want to be very disciplined in our approach to launching a new robotic system to make sure that we do it right. We have the right education. We have the right service levels. And we will do that limited launch for, let’s call it six months. Post that limited launch is when we move into full launch. And that’s when the organization gets unleashed and we utilize that technology in that full launch status.”

Needham & Co.’s Mike Matson published an analysis Wednesday of the potential impact of the anticipated full launch. In particular, Matson looked at how Rosa might impact Stryker’s Mako robot, which garnered impressive revenue during the fourth quarter of 2018.

Interestingly, Stryker also took a conservative approach to its Mako launch. The Kalamazoo, MI-based company made the market wait more than a year after FDA approval for the full commercial launch of its Mako total knee product. In Stryker’s case, the product proved to be well worth the wait.

Zimmer Biomet has lost knee market share on a year-over-year basis in nearly every quarter since the Zimmer-Biomet merger, according to Matson. The full launch of the Rosa Knee is likely to change that story though. The analyst also noted that the company’s share loss can be attributed to supply issues and other product gaps, not just the lack of a robotics offering. He also acknowledged that the share loss did slow last year as Zimmer Biomet began to address its supply issues.

By Amanda Pedersen | MD+DI

Image Credit: Zimmer Biomet

READ MORE

About Peter Coffaro 487 Articles
A growth-driven and strategic executive, Peter Coffaro commands more than 25 years of progressive management success within the medical device industry. Recognized by the World Journal of Orthopedics, Exponential Healthtech, and MedReps.com as one of the top medical sales influencers in the industry; he has 10 years of combined sales management experience and has held positions as a Director, General Manager, Distributor, and Vice President. Peter has worked for some of the top orthopedic companies in the world - Zimmer, DePuy, and Stryker. He is also the founder of OrthoFeed: a popular blog that covers digital orthopedic news and emerging medical technologies. Peter is a three-time Hall of Fame award winner at Johnson and Johnson and has an extensive background in organizational development, business development, sales management, digital marketing, and professional education. Peter holds a B.S. degree in Biology and Chemistry from Northern Illinois University.

Be the first to comment

Leave a Reply

Your email address will not be published.


*


This site uses Akismet to reduce spam. Learn how your comment data is processed.